Management of anemia in patients with cancer: 2019 Italian Association of Medical Oncology (AIOM) guidelines
- 2 June 2020
- journal article
- review article
- Published by SAGE Publications in Tumori Journal
- Vol. 106 (5) , 337-345
Abstract
This article summarizes the latest Italian Medical Oncology Association (AIOM) guidelines on the management of cancer-related and chemotherapy-related anemia with a particular attention to the use of erythropoiesis-stimulating agents and iron supplementation.Keywords
This publication has 39 references indexed in Scilit:
- Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancerBritish Journal of Cancer, 2012
- Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated AnemiaJournal of Clinical Oncology, 2011
- Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for useAnnals of Oncology, 2010
- Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomesBritish Journal of Cancer, 2010
- Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic MechanismsJournal of Clinical Oncology, 2009
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCanadian Medical Association Journal, 2009
- Impact of limiting erythropoiesis‐stimulating agent use for chemotherapy‐induced anemia on the United States blood supply marginTransfusion, 2009
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEuropean Journal of Cancer, 2007
- Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfaEuropean Journal of Cancer, 2005